Navigation Links
Inventive combination of research approaches identifies new target for treating leukemia
Date:10/5/2009

New research integrates sophisticated interdisciplinary approaches to solve a molecular mystery that may lead to alternative therapeutic strategies for acute myeloid leukemia (AML). The study, published by Cell Press in the October issue of the journal Cancer Cell, identifies a previously unrecognized AML target that responds well to pharmacological inhibition and may be an excellent candidate for use in future clinical trials.

AML is a type of blood cancer that disrupts normal blood cell production. "Long term survival for patients with AML remains poor despite dose-intensive chemotherapy regimens," explains senior study author, Dr. Kimberly Stegmaier from Dana-Farber Cancer Institute, Broad Institute of Harvard and MIT, and Children's Hospital Boston. "For older adults, long-term survival is dismal, and many older patients are unable to tolerate standard cytotoxic therapy." Unfortunately, identification of new treatment strategies has proven difficult as many potential targets are proteins that do not respond well to standard pharmacological methods.

Another challenge has been to unravel the molecular mechanisms associated with compounds that inhibit or reverse AML progression. Target identification is necessary for optimization of drug treatment. Dr. Stegmaier and colleagues had previously demonstrated that epidermal growth factor receptor (EGFR) inhibitors exhibited anti-AML activity. However, this finding was somewhat puzzling as EGFR is not expressed in AML. The researchers made use of sophisticated cross-disciplinary approaches to study gene expression (genomics) and protein structure and function (proteomics) to elucidate the molecular basis for the effect of EGFR inhibitors in AML.

Spleen tyrosine kinase (Syk) was identified as a target in AML. Syk is expressed in blood cells and is critical for proper blood cell differentiation. Recent research has implicated Syk in blood cancers, specifically lymphomas and leukemia
'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Modern Health Care Economics is Driving Inventiveness in Delivery of Cancer Surgery and Management of Risk
2. Combination of PET/CT tests can expedite diagnosis of lung cancer in a fast-track setting
3. Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
4. Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study
5. More Sleep & Less Sex - A Losing Combination
6. Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
7. Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice
8. Mega-Catch™ 3000 Combination Lure Attracts Asian Tiger Mosquitoes (Aedes Albopictus)
9. Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination
10. Large Majority of Drivers 55 and Older Unaware of Potentially Dangerous Combination of Medications and Driving, Says New AAA Foundation Study
11. BBV Vietnam S.E.A. Acquisition Corp. Announces Signing of Letter of Intent for Business Combination with Migami, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ... platform to think outside the bra. She doesn’t try to ... raise awareness about women’s other lady parts. , "We have ... the color pink and everybody knows what you’re talking about,” ... it has not been won when it comes to gynecologic ...
(Date:10/20/2014)... 2014 Myoderm announced ... Director of their CentralSource service. Matthew ... innovative turnkey drug sourcing, distribution, and management service ... 12 years of industry experience, in both business ... peak of their international success to help clients ...
(Date:10/20/2014)... Viejo, California (PRWEB) October 20, 2014 Final ... announced the release of the Citrus theme for FCPX ... I would use to describe the Citrus theme” Says Christina ... so easy to look so professional.” , Citrus comes with ... Included with the template are: four transitions for added style, ...
(Date:10/20/2014)... 20, 2014 Do you ever feel ... comes a wonderful app Metassessor for teachers, specialists and ... helped its client “Intervention Development LLC” to launch ... is designed for iOS 4.3 or later and is ... is optimized for iPhone 5. It is now available ...
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... therapeutic development for Partial Seizure, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Partial Seizure and special features on late-stage ...
Breaking Medicine News(10 mins):Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... announced that it has launched the authorized generic version of ... ,The company has also launched the authorized generic ... 20 mg, 40 mg and 80 mg yesterday, a company ... entered into separate agreements with Merck that enabled it to ...
... women-only Fatima Jinnah University in Rawalpindi is embroiled in ... ,Opposition members in the National Assembly protested ... sister of Mohammad Ali Jinnah, the founder of Pakistan. ... Daily Times that a portion of the campus had ...
... Sciences (AIIMS) is contemplating leaving the institution, saying he has ... ,"The day I became the dean of AIIMS, ... University in Lucknow. I declined the offer then but might ... R.C. Deka, a leading ENT surgeon in the country and ...
... the numbers of heart transplants are on the decline. This ... properly//. Hence the doctors at the Papworth Hospital in Cambridge ... for five hours after it was removed from the donor. ... transplant was Michael Burt, 58, a builder from Burnham Market, ...
... that researchers will be able to re-establish growth ... by deafness//. ,These tiny hairs in the ear are capable ... into sound. Once lost, these hairs could not be ... one out of every twenty-four people, across the globe, suffered ...
... researchers show that the male survivors of childhood ... recognized and understood// many health care practitioners as ... though both male and female childhood sexual survivors ... about their encounters with health care professionals, there ...
Cached Medicine News:Health News:'Humiliated' Dean Contemplates Leaving AIIMS 2Health News:'Humiliated' Dean Contemplates Leaving AIIMS 3Health News:Latest In the Heart Transplant Field 2Health News:Sexually Abused Males Found Struggling In heir relations with Healthcare Providers 2
(Date:10/17/2014)...  Amgen (NASDAQ: AMGN ) today announced ... president of Gladstone Institutes and Gladstone,s Robert W. and ... are pleased to welcome Dr. Sandy Williams ... , chairman and chief executive officer of Amgen. "Dr. ... his direct experience in our industry will both be ...
(Date:10/17/2014)... 17, 2014 Research and Markets ... and Development Prospect of China Dialysis Market, 2014-2018" ... Based on the 2013 version, this update Report ... dialysis industry and the relevant effect in recent ... industry segmentations. Moreover, it analyzes Chinese private-owned hemodialysis ...
(Date:10/17/2014)... 17, 2014 A victim of medical negligence at ... doctor with a history of alcohol abuse, a physician and ... Prop 46 today, highlighting how Prop 46 will identify and ... The ad pictures a doctor drinking at ... ER."  Proposition 46 will enact the first law in the ...
Breaking Medicine Technology:Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4
... Research Group (MRG), the global authority on medical technology ... a highly competitive and dynamic market, with a small ... this extremely profitable area. As of 2010, the drug-eluting ... most lucrative of the interventional cardiology device markets.   ...
... 5 Osseon Therapeutics, Inc. announced its new ... American Spine Society,s (NASS) annual meeting in Orlando, ... treatment of vertebral compression fractures (VCFs) that may ... metastases.  The Osseoflex DR Steerable Bone Drill features ...
Cached Medicine Technology:Canadian Health Care System Pressuring Manufacturers to Lower Drug-Eluting Stent Prices in US$55 Million Market 2Canadian Health Care System Pressuring Manufacturers to Lower Drug-Eluting Stent Prices in US$55 Million Market 3Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill 2
Cytomegalovirus IgM ELISA....
Microforceps: Diamond Dusted Micro Pic Forceps...
Ultra-fine pointed forceps with diamond dusting on inner tip surface for enhanced grasping of tissue. Ideal for fine membrane grasping....
The Tano Asymmetrical Microforceps features an offset tip which allows optimal visualization along the entire tip length. Versatile tip design targets ILM, fine epiretinal membranes and diabetic or P...
Medicine Products: